
Sep 24, 2026
Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY)
Oppenheimer analyst Andreas Argyrides has reiterated an Outperform rating for Harmony Biosciences Holdings Inc. (NASDAQ: HRMY). The firm also maintained a $70.00 price target for the company's stock. The full analyst report is available to premium subscribers.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish